PUMA
The final episode of PUMA’s RE:GEN REPORTS is now available to stream: ‘When it comes to Health and Safety, does the West know best?’. In this episode, hosted by the Head of Knowledge Exchange at the Centre for Sustainable Fashion, Monica Buchan-Ng, PUMA’s Chief Sourcing Officer, Anne-Laure Descours, reminds audiences that it’s important for people in the North to “recognize how much people on the ground are trying to improve [factory working conditions].”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230801314932/en/
The final episode of PUMA’s RE:GEN REPORTS is now available to stream: ‘When it comes to Health and Safety, does the West know best?’. (Photo: Business Wire)
The podcast series aims to make PUMA’s 2022 Sustainability Report more accessible to a wider and younger audience. This came after research conducted last year which found that young people want brands to be more transparent with consumers when it comes to the environment and sustainability (34%) and to communicate their goals better (40%).
In 2022 PUMA hosted Conference of the People, where Gen Z representatives, PUMA’s industry peers, activists, NGOs, experts, ambassadors, and consumers met to discuss some of the fashion industry’s sustainability challenges. The conference also highlighted the need for PUMA to improve on how it was communicating sustainability goals, actions, and progress.
RE:GEN REPORTS is hosted by 10 next-generation thinkers from six countries, distilling the content of the brand’s sustainability report into 10 episodes. Each host was tasked with breaking down the complex topics into digestible pieces. Focusing on PUMA’s sustainability strategy FOREVER.BETTER. 10FOR25 sustainability targets, the podcasts were created to eliminate barriers of traditional sustainability language, explaining why the specific targets were a focus for the business. Episodes discuss progress that has been made, whilst acknowledging areas where there is still work to be done.
From a 147-page report and over thirty hours of recording came this 163-minute series of clear and relatable sustainability information. As well as the final episode on health and safety, young people guided audiences through episodes about: human rights, hosted by Award-winning activist, model, and social entrepreneur Anya Dillard from the USA; chemicals, hosted by sustainable and healthy living vlogger Luke Jaque-Rodney from Germany; circularity, hosted by USA-based upcycler Andrew Burgess; fair wages, hosted by Fair Labor Association student committee member Amina Shakeel; climate action, hosted by Earthero Project co-founder Bertha Shum from Hong Kong; biodiversity hosted by India-based environmental activist Ripudaman Bevli; plastic & oceans, hosted by Singapore sustainable bag company Peco Bag founder Yumika Hoskin; product, hosted by intersectional environmentalist Diandra Marizet from the US and water and air, hosted by Malaysian based eco-conscious Earth Day Ambassador Melissa Tan .
As well as PUMA spokespeople, the young hosts also interviewed representatives from industry bodies, businesses, and NGOs in discussions around the implementation and monitoring of more sustainable practices. Guests included Fair Labor Association’s Chief of Staff, Shelly Han; UNFCCC’s Sector’s Engagement in Climate Action Lead, Lindita Xhaferi-Salihu; Canopy’s Founder and Executive Director, Nicole Rycroft; ZDHC Implementation Director, Klass Nuttbohm; Apparel Impact Institute’s Chief Impact Officer, Kurt Kipka; and Leather Working Group’s Traceability Manager, Vanessa Brain.
“Transparency is critical to our sustainability strategy at PUMA,” says Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We are committed to improving our practices and equally acknowledging where there is still a way for us to go. We invited these next generation thinkers to interview us and our partners on our FOREVER.BETTER. sustainability strategy 10FOR25 targets to push us to be better, to do better, and get into the detail in a way that more people can access and understand. It’s easy to hide areas where you’re not making progress as quickly as you’d like, but change requires collaboration and openness and with RE:GEN REPORTS we have and will continue to welcome both of those things.”
PUMA’s sustainability efforts have been recognized several times. In 2022, the brand topped the Business of Fashion sustainability ranking, the platform on living wage financials ranking, and the FTSE4Good ranking within its sectors. It was included in the Corporate Knights global top 100 most sustainable companies ranking, maintained its triple-A ranking with MSCI and its prime status with ISS; two leading sustainability rating agencies. Reuters also ranked it as number two within its sector and, in S&P sustainability benchmarking, PUMA outperformed all other sports brands for the first time since 2010. Although these rankings help confirm that PUMA is headed in the right direction with its FOREVER.BETTER. sustainability strategy, the brand recognizes that it still has a long way to go.
PUMA’s full 2022 Sustainability Report can be accessed here.
PUMA |
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801314932/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom